Hillstream BioPharma Stock Price, News & Analysis

Hillstream BioPharma, Inc. (NASDAQ: HILS) is a cutting-edge biotechnology company dedicated to developing innovative therapeutic candidates targeting drug-resistant and devastating cancers. The company's proprietary Quatramer™ technology enables targeted delivery and extended action of biologics, mRNA, peptides, and other therapeutic modalities within the tumor microenvironment, minimizing off-target toxicity.

Hillstream's notable advancements include Quatrabody™ conjugates, which exhibit higher binding affinity to immuno-oncology targets than currently approved therapies. Emerging as a leader in immuno-oncology, Hillstream is set to enter the market with its leading candidate HSB-1940, targeting PD-1, followed by other targets such as PD-L1, HER-2, and TROP-2.

Recent achievements highlight Hillstream's exclusive license agreement with the Applied Biomedical Science Institute (ABSI), which allows the company to develop novel antibodies targeting HER2 and HER3. These antibodies are distinct from existing therapies and present a promising approach to treating HER2-positive cancers.

Hillstream's focus on oncology includes developing HSB-3215, a bi-specific antibody targeting HER2 and HER3. Through collaborations with Minotaur Therapeutics and OmniAb, Inc., Hillstream is advancing the development of next-generation biotherapeutics, including Picobodies™ against HER3 and other undisclosed oncology targets.

In addition to oncology, Hillstream is expanding its therapeutic pipeline with the acquisition of AV104, a clinical-stage asset for treating chronic pruritis, including conditions such as primary biliary cholangitis (PBC). This asset utilizes a proprietary transdermal buccal film for effective delivery and high drug concentrations in the skin.

Hillstream BioPharma's strategic focus on advancing its robust immuno-oncology pipeline and acquiring clinical-stage assets positions the company as a significant player in the biotechnology sector. For further information, please visit www.hillstreambio.com.